Biohaven and Pfizer announce positive topline results of rimegepant to treat migrane
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
It will showcase the company’s latest technologies in robotics, digital health and orthopaedic implants
FortePhest is developing a new technology to combat herbicide-resistant weeds and invasive plants
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
Subscribe To Our Newsletter & Stay Updated